[{"orgOrder":0,"company":"PeriphaGen","sponsor":"Candel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Acquisition","leadProduct":"rQNestin34.5","moa":"ICP34.5","graph1":"Oncology","graph2":"Phase I","graph3":"PeriphaGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PeriphaGen \/ Candel Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"PeriphaGen \/ Candel Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by PeriphaGen

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : This acquisition solidifies Candel’s viral therapy leadership position and supports further development of Candel’s rQNestin34.5, currently in a Phase 1 study for recurrent malignant gliomas.

                          Product Name : Undisclosed

                          Product Type : Microorganism

                          Upfront Cash : Undisclosed

                          August 01, 2020

                          Lead Product(s) : rQNestin34.5

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Candel Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank